This trial shows why the assessment date belongs beside a response rate. A treatment-end comparison and a later follow-up comparison need not tell the same story. Primary report
What was reported
Ninety-eight participants were allocated to two thymosin-alpha-1 treatment durations or an untreated control group. Response rates were similar at treatment completion but differed at the 18-month assessment: the shorter treatment group's comparison with control was statistically significant, while the longer treatment group's comparison was not. The report defined virological response using HBV DNA and HBeAg; none of the responders lost HBsAg. Primary report
Our appraisal: do not compare significance labels instead of groups
One comparison reaching a threshold while another does not is not itself a test of the difference between the two active regimens. A claim that the shorter course is superior would require the direct comparison and its uncertainty, not subtraction of two significance labels.
The viral-marker distinction is equally important. A reader seeing “clearance” may assume all relevant viral markers disappeared. Naming the measured markers prevents a narrower response from becoming a broader cure claim.
Finally, delayed observations need a follow-up accounting: who remained under observation, when testing occurred, and how missing tests were handled. If the treatment periods differ, calendar time since enrollment and time since treatment ended also differ. Those clocks should not be silently combined.
This historical study can inform an evidence map, but it does not by itself establish a modern standard of care or a protocol for research-grade materials.
Frequently asked questions
Was the control group given placebo?
The abstract describes an untreated control group.
Did the assessment date matter?
Yes. Treatment-end and later results differed.
Did responders lose HBsAg?
The report says none did.
Does significance in only one arm prove the arms differ?
No. That requires a direct between-arm comparison.
Are all viral markers interchangeable?
No. Each response definition must name its markers.
Does this establish a treatment schedule for readers?
No. The page interprets evidence rather than prescribing care.
What remains pending?
Full methods, participant follow-up, direct comparisons, and safety review.